Bionovo Inc. Tenbagger !
Seite 1 von 1 Neuester Beitrag: 29.03.12 08:36 | ||||
| Eröffnet am: | 21.03.12 16:34 | von: Greys | Anzahl Beiträge: | 9 |
| Neuester Beitrag: | 29.03.12 08:36 | von: Greys | Leser gesamt: | 4.149 |
| Forum: | Hot-Stocks | Leser heute: | 1 | |
| Bewertet mit: |  | |||
Hier lauern nach dem Abschluß einer Finanzierung schnell 150 - 200 %
Bionovo, Inc.(Bionovo) ist ein US-amerikanisches Biopharma-Unternehmen im Bereich Entdeckung und Entwicklung von sicheren und wirksamen Arzneimitteln zur Behandlung von BrustKrebs u. a. Krebsarten.
LifeTech Capital Maintains Bionovo Strong Speculative Buy, Lowers PT
Posted on 08/03/11 at 1:41pm by Olivia Lange [1]
LifeTech Capital maintained its Bionovo (NASDAQ: BNVI [2]) Strong Speculative Buy rating and lowered its Bionovo price target from $7.50 to $5 in a research report published today.
In the report, LifeTech Capital states, "Menerba could become the first botanical blockbuster drug which we believe represents an intriguing opportunity for patient investors."
Shares of Bionovo were trading at $0.69 at the time of posting, down 12.41% from Tuesday's market close.
March 21, 2011 Rating Target
Strong Speculative Buy
$7.50
http://www.lifetechcapital.com/reports/BNVI%20Update%2003-21-11.pdf
http://www.bosa.co.kr/umap/sub.asp?news_...
Article Date: 2012-03-22 11:22:08 AM
Five three-phase attention as a promising new drug candidates
Menopause and High Cholesterol drug side effects, including reduced
Reduce the side effects of conventional treatment of familial hypercholesterolemia and treatment of menopausal symptoms, such as three-phase drug candidates has been noted as a prospect.
In addition, Thomson Reuters in the world during the last quarter phase III trial of new drug candidates entered the Pseudomonas aeruginosa infections, allergies, gout cure was chosen primarily expected 5.
First, bio-Novo (Bionovo) treatment of menopausal hot flashes and night sweats Jane meneoba '(Menerba) an oral plant-derived estrogen receptor beta agonist in the risk of breast and cervical cancer as an alternative to hormone replacement therapy is expected.
That activation of estrogen receptor alpha to increase the risk of cancer of the breast tissue, but the activation of receptor beta to inhibit the growth is affected. In previous clinical studies hormone therapy and the effect was similar but safety.
http://seekingalpha.com/article/...hip-filings-this-week?source=yahoo
"Empery filed a SEC Form SC 13G on Monday indicating that it holds 4.91 million shares or 9.9% of outstanding shares, and warrants to purchase an additional 5.74 million shares of BNVI, a clinical-stage drug discovery and development company that focuses on developing drug candidates in the areas of women's health and cancer. Besides Empery, New York-based multi-strategy hedge fund Hudson Capital Management also filed SEC Form SC 13G today indicating that it holds 4.50 million shares, and warrants to purchase an additional 5.74 million shares."
Optionen
| Boardmail an "celi-michi" |
Wertpapier: Bionovo |
Bionovo's Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™
2012-03-28 11:59 ET - News Release
EMERYVILLE, Calif., March 28, 2012 /PRNewswire/ -- Bionovo, Inc. (OTCQB: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that the Company's independent Data Safety Monitoring Board (DSMB) recommended that the Phase 3 trial of Menerba (MF101) could continue as designed after an initial review of its clinical safety and tolerability data. Menerba is Bionovo's oral botanical drug candidate designed for the safe and effective treatment of vasomotor symptoms (hot flashes) associated with menopause. The DSMB evaluated unblinded safety and dose tolerability data after 66 participants were randomized and on study medication for at least 30 days. After an independent review of the data, the DSMB issued their positive recommendation to continue the trial as originally designed and no concerning safety signals were identified. "I am very encouraged by the positive recommendation from our independent DSMB. This assurance that Menerba™ continues to be a safe, well-tolerated, non-estrogen alternative therapy for the treatment of menopausal hot flashes is consistent with the promising results of our early clinical trial data and extensive pre-clinical toxicity studies. We are very eager to continue to develop a safe and effective treatment for post-menopausal hot flashes, a drug that can be the leading seller in the well established multibillion dollar market," said Mary Tagliaferri, M.D., Bionovo's President and Chief Medical Officer. The MF101-004 Phase 3 pivotal study dosed its first patient on November 16, 2011. To date, a total of 280 postmenopausal women have been randomized to the trial. Recruitment to the Phase 3 trial was voluntarily halted on March 9, 2012 as Bionovo does not have adequate funding to further advance the registration trial. Bionovo will need to secure additional financing to complete either a smaller Phase 2B trial with the current cohort of 280 randomized participants or to complete the planned Phase 3 study. The purpose of the study is to evaluate the safety and efficacy of two doses of Menerba™ (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes. (Logo: http://photos.prnewswire.com/prnh/20111110/SF04662LOGO) Participants are randomized to Menerba™ 5g/day, Menerba™ 10g/day or placebo and treated for 12 weeks. E